Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 3

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 3
---
ation on redemption rights of shareholders holding more than 15% of the shares sold in this offering if we hold shareholder vote.” Our public shareholders will be permitted to redeem their shares regardless of whether they abstain, vote for, vote against, or vote at all with respect to the proposed business combination. If we are unable to complete our initial business combination within 15 months from the closing of this offering, the time period to complete an initial business combination can be extended without shareholder approval up to two times, each by an additional three months (for a total of up to 21 months to complete an initial business combination from the closing of this offering), subject to our sponsor depositing into the trust account $0.10 per public share outstanding in connection with each such extension. We refer to the time period we have to complete an initial business combination, as it may be extended as described above, as the “completion window.” If our completion window is extended by our sponsor as described above, our shareholders will not be entitled to vote on or redeem their shares in connection with any such extension. If we have not completed our initial business combination within the completion window, we will redeem 100% of the issued and outstanding public shares at a per -shareprice, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (net of funds withdrawn to pay our taxes, if any, and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and as further described herein. Our sponsor, Drugs Made In America Acquisition LLC, a Delaware limited liability company (which we refer to as our “sponsor” throughout this prospectus), has committed to purchase an aggregate of 400,000 units, or “private units” (or 430,000 private units if the underwriters’ option to purchase additional units is exercised in full) at a price of $10.00 per unit ($4,000,000 in the aggregate, or $4,300,000 in the aggregate if the underwriters’ option to purchase additional units is exercised in full) in a private placement that will close simultaneously with the closing of this offering. Each private unit will consist of one ordinary share and one right to receive one -eighth(1/8) of an ordinary share upon the consummation of an initial business combination. We refer to the shares included in the private units throughout this prospectus as the “private shares” and the rights